Immuno-Biological Laboratories Co Ltd
TSE:4570
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
14.1B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
203.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
152.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
75.9T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.4B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
31.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.6B USD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Immuno-Biological Laboratories Co Ltd
Glance View
Immuno-Biological Laboratories Co., Ltd. engages in the manufacture and sale of antibody-related reagents and pharmaceutical products. The company is headquartered in Fujioka-Shi, Gumma-Ken(Gunma-Ken) and currently employs 65 full-time employees. The company went IPO on 2007-03-02. The firm operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Immuno-Biological Laboratories Co Ltd is 31.6%, which is above its 3-year median of 8%.
Over the last 3 years, Immuno-Biological Laboratories Co Ltd’s Net Margin has increased from -28.5% to 31.6%. During this period, it reached a low of -36.5% on Mar 31, 2023 and a high of 31.6% on Dec 31, 2024.
